Development of Genetically Engineered Mouse Models for NF1-associated Optic Pathway Gliomas

To facilitate the translation into clinical practices, the Zhu lab will employ two clinically relevant assays to characterize these NF1-OPG models, the optomotor response (OMR) assay for estimating visual acuity and (2) the OCT assay as an indirect estimation for axonal loss of RGCs. Following the OMR and OCT assays, the NF1-OPG models will be analyzed by histopathologic or electrophysiologic assays to determine structural or functional abnormalities caused by NF1-OPG. Further, novel therapeutic strategies for axonal regeneration will be tested on a novel NF1-OPG model with surviving RGCs.

Investigators

Yuan Zhu, PhD

Children’s National Health System

Yuan Zhu, PhD

Children’s National Health System

Current Stage

Discovery

Discovery
In Vivo Proof of Concept
IND Enabling
Clinical Trial Phase 1
Clinical Trial Phase 2
Clinical Trial Phase 3